Reduction of PRC2 activity supports survival of TNBC cancer cells to cytotoxic treatments. Reduction of PRC2 activity supports survival of TNBC cancer cells to cytotoxic treatments

Basal-like breast cancer generally shows a good response to conventional cytotoxic but rapidly develops a resistant phenotype. To better understand the epigenetic changes underlying the acquisition of resistant properties, we treated the murine basal-like mammary carcinoma cell line G-2 for 48 hours with sublethal combination chemotherapy (Cyclophosphamide, Adriamycin, 5-Fluorouracil) and subsequently subjected them to RNA- and ChIP-sequencing.